Medicare has served our nation well, providing medical benefits and retirement
security for millions of Americans. As you may know, Congress and the Trump
administration have been working on ways to help lower the cost of prescription
Medicare prescription drug coverage (Part D) contains a coverage gap referred
to as a “donut hole.” This means that after a patient, and their drug plan, have
spent up to a certain threshold, the patient has to pay the remaining costs out-of-
pocket up to a yearly “catastrophic coverage” limit before the coverage gap
ends and the drug plan helps cover the costs again.
By signing the 2018 government funding bill into law, President Trump agreed
to close the “donut hole” for Part D enrollees. The Medicare Part D "donut hole"
will be closing for brand-name drugs in 2019 and generic drugs in 2020. Come
2020, the “donut hole” will be completely closed and Part D beneficiaries will
no longer be forced to shoulder the full burden of this gap in prescription
coverage—a long overdue fix.
Additionally, Congress has passed, and yesterday
President Trump signed into law, a pair of bills that will increase drug pricing
transparency. The Patient Right to Know Drug Prices Act and the Know the
Lowest Price Act will eliminate “gag clauses” that have prevented pharmacists
from telling customers whether or not they can save money through out-of-
pocket expenditures instead of through their health plans—allowing patients
to get the lowest available price while simultaneously increasing transparency
in the marketplace.
While health care costs continue to rise, know that I’m working on solutions
that provide transparency, reduce costs, increase quality, and empower patient
It's an honor to serve you and Virginia's First District in the People's House.
Congressman Rob Wittman